Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

It is the highest number of cases recorded since the virus became notifiable. A free RSV vaccine will be made available to pregnant people to protect them and their unborn babies from February 3.

COVID-19 and flu activity is increasing in most parts of the country and RSV activity remains very high, especially in young children. Respiratory illness activity in Florida is very high ...

It's flu season. And COVID season. And RSV season. The Centers for Disease Control and Prevention (CDC) reported that as of last week, "the amount of acute respiratory illness causing people to ...